Lyell Immunopharma, Inc.
LYEL
$10.64
-$0.33-3.01%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 18.22% | 72.81% | -330.51% | 2.68% | 24.49% |
| Total Depreciation and Amortization | -8.89% | -31.54% | 7.39% | -4.51% | -2.45% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 67.14% | -97.44% | 3,551.49% | 1.49% | -77.66% |
| Change in Net Operating Assets | 90.83% | -28,200.00% | -96.72% | 208.70% | 70.53% |
| Cash from Operations | 37.05% | -15.87% | -34.82% | 8.01% | 9.33% |
| Capital Expenditure | 31.71% | -459.09% | 25.42% | 82.18% | -1,003.33% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -81.62% | -17.88% | 4,194.13% | -95.64% | 105.86% |
| Cash from Investing | -81.79% | 29.83% | 2,689.62% | -95.74% | 104.63% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -100.00% | 736.89% |
| Repurchase of Common Stock | -- | -- | -- | -- | 100.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -200.00% | -- | -- | -- | -- |
| Cash from Financing | 18,200.00% | -99.77% | -- | -100.00% | 3,092.59% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -246.84% | 119.84% | 120.23% | -526.03% | 138.88% |